Merck Tbk (MERK) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Merck Tbk (MERK) has a cash flow conversion efficiency ratio of 0.166x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rp137.63 Billion ≈ $8.06 Million USD) by net assets (Rp829.78 Billion ≈ $48.62 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See MERK equity to assets ratio to measure how much of total assets are equity-financed.
Merck Tbk - Cash Flow Conversion Efficiency Trend (2000–2024)
This chart illustrates how Merck Tbk's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Merck Tbk (MERK) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Merck Tbk Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Merck Tbk ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Amica S.A.
WAR:AMC
|
0.059x |
|
Papoutsanis S.A
AT:PAP
|
-0.084x |
|
Entre Cua Socimi
MC:YENT
|
0.013x |
|
Black Diamond Therapeutics Inc
NASDAQ:BDTX
|
-0.098x |
|
Loxley Public Company Limited
BK:LOXLEY
|
-0.044x |
|
Marks and Spencer Group PLC
LSE:MKS
|
0.289x |
|
KB Star REIT Co. Ltd.
KO:432320
|
0.005x |
|
Kreate Group Oyj
HE:KREATE
|
0.254x |
Annual Cash Flow Conversion Efficiency for Merck Tbk (2000–2024)
The table below shows the annual cash flow conversion efficiency of Merck Tbk from 2000 to 2024. For the full company profile with market capitalisation and key ratios, see Merck Tbk stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Rp807.27 Billion ≈ $47.30 Million |
Rp55.71 Billion ≈ $3.26 Million |
0.069x | -73.06% |
| 2023-12-31 | Rp795.88 Billion ≈ $46.64 Million |
Rp203.87 Billion ≈ $11.95 Million |
0.256x | +75.83% |
| 2022-12-31 | Rp757.24 Billion ≈ $44.37 Million |
Rp110.32 Billion ≈ $6.46 Million |
0.146x | -41.31% |
| 2021-12-31 | Rp684.04 Billion ≈ $40.08 Million |
Rp169.81 Billion ≈ $9.95 Million |
0.248x | +111.30% |
| 2020-12-31 | Rp612.68 Billion ≈ $35.90 Million |
Rp71.98 Billion ≈ $4.22 Million |
0.117x | +133.10% |
| 2019-12-31 | Rp594.01 Billion ≈ $34.81 Million |
Rp-210.84 Billion ≈ $-12.35 Million |
-0.355x | -208.88% |
| 2018-12-31 | Rp518.28 Billion ≈ $30.37 Million |
Rp168.96 Billion ≈ $9.90 Million |
0.326x | +54.43% |
| 2017-12-31 | Rp615.44 Billion ≈ $36.06 Million |
Rp129.92 Billion ≈ $7.61 Million |
0.211x | +180.84% |
| 2016-12-31 | Rp582.67 Billion ≈ $34.14 Million |
Rp43.80 Billion ≈ $2.57 Million |
0.075x | -77.85% |
| 2015-12-31 | Rp473.54 Billion ≈ $27.75 Million |
Rp160.70 Billion ≈ $9.42 Million |
0.339x | -19.30% |
| 2014-12-31 | Rp553.69 Billion ≈ $32.44 Million |
Rp232.83 Billion ≈ $13.64 Million |
0.420x | +61.82% |
| 2013-12-31 | Rp512.22 Billion ≈ $30.01 Million |
Rp133.10 Billion ≈ $7.80 Million |
0.260x | +22.49% |
| 2012-12-31 | Rp416.74 Billion ≈ $24.42 Million |
Rp88.40 Billion ≈ $5.18 Million |
0.212x | -32.90% |
| 2011-12-31 | Rp494.18 Billion ≈ $28.96 Million |
Rp156.23 Billion ≈ $9.15 Million |
0.316x | -28.09% |
| 2010-12-31 | Rp363.02 Billion ≈ $21.27 Million |
Rp159.58 Billion ≈ $9.35 Million |
0.440x | +91.60% |
| 2009-12-31 | Rp354.18 Billion ≈ $20.75 Million |
Rp81.26 Billion ≈ $4.76 Million |
0.229x | -27.60% |
| 2008-12-31 | Rp327.32 Billion ≈ $19.18 Million |
Rp103.73 Billion ≈ $6.08 Million |
0.317x | +28.61% |
| 2007-12-31 | Rp280.23 Billion ≈ $16.42 Million |
Rp69.05 Billion ≈ $4.05 Million |
0.246x | -36.50% |
| 2006-12-31 | Rp235.58 Billion ≈ $13.80 Million |
Rp91.42 Billion ≈ $5.36 Million |
0.388x | +79.51% |
| 2005-12-31 | Rp180.38 Billion ≈ $10.57 Million |
Rp38.99 Billion ≈ $2.28 Million |
0.216x | -39.90% |
| 2004-12-31 | Rp154.04 Billion ≈ $9.03 Million |
Rp55.40 Billion ≈ $3.25 Million |
0.360x | -11.02% |
| 2003-12-31 | Rp159.51 Billion ≈ $9.35 Million |
Rp64.48 Billion ≈ $3.78 Million |
0.404x | +113.28% |
| 2002-12-31 | Rp149.25 Billion ≈ $8.75 Million |
Rp28.29 Billion ≈ $1.66 Million |
0.190x | -38.74% |
| 2001-12-31 | Rp127.49 Billion ≈ $7.47 Million |
Rp39.44 Billion ≈ $2.31 Million |
0.309x | -24.27% |
| 2000-12-31 | Rp96.86 Billion ≈ $5.68 Million |
Rp39.57 Billion ≈ $2.32 Million |
0.409x | -- |
About Merck Tbk
PT Merck Tbk engages in the manufacture and sale of pharmaceutical products in Indonesia and internationally. The company operates through Biopharma, Consumer Health, and Others segments. It offers health care products in the areas of cardiovascular, metabolic, oncology, endocrinology, fertility, and neurodegenerative diseases, as well as general medicines. The company also engages in research an… Read more